Friday, September 23, 2011
Advanced Cell Technology Inc., of Marlborough, Mass., has received clearance from the UK Medicines and Healthcare products Regulatory Agency to treat patients as part of a Phase I/II trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelium (RPE) derived from human embryonic stem cells.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.